Long-term Follow-up of Subjects Treated With CAR T Cells

Recruiting now

Conditions studied: Long Term Adverse Effects, CAR-T, Duty to Follow Up, Adult, Progression-Free Survival, Disease-Free Survival, Overall Survival

In brief

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (DF/HCC# 22-175) and NCT06026319 (DF/HCC# 23-474).

Key facts

Study ID

NCT05024175

Run by

Marcela V. Maus, M.D.,Ph.D.

People needed

45

Starts

2023-08-07

Expected to finish

2039-08-01

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be asked to participate leading up to the last DF/HCC corresponding main study visit.
• Subjects meeting the following criteria are eligible for study participation:
• Provision of voluntary written informed consent by subject
• CAR T cells were administered in DF/HCC IRB corresponding main study

You may not qualify if…

• Subjects meeting the following criterion are to be excluded from study participation:
• Subject unable to comply with study requirements

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.